5‐Methoxy‐ <i>N</i> , <i>N</i> ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

A first phase 2a clinical trial of 5-methoxy-N,N-dimethyltryptamine (BPL-003 10 mg) in the context of a 10-week programme of CBT demonstrated acceptable safety and tolerability and provided preliminary evidence of efficacy for reducing alcohol craving and consumption. These findings support progression to larger, controlled trials of BPL-003 for the treatment of alcohol use disorder.